Get the Stockscreener App
8.32
2.09%
0.17
After Hours:
8.32
Treace Medical Concepts Inc stock is traded at $8.32, with a volume of 347.71K.
It is up +2.09% in the last 24 hours and down -6.94% over the past month.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
See More
Previous Close:
$8.15
Open:
$7.99
24h Volume:
347.71K
Relative Volume:
0.92
Market Cap:
$510.34M
Revenue:
$198.53M
Net Income/Loss:
$-63.68M
P/E Ratio:
-8.1393
EPS:
-1.0222
Net Cash Flow:
$-41.50M
1W Performance:
-3.03%
1M Performance:
-6.94%
6M Performance:
+52.66%
1Y Performance:
-30.67%
1-Day Range:
$7.85
$8.35
1-Week Range:
$7.85
$8.87
52-Week Range:
$3.92
$12.74
Treace Medical Concepts Inc Stock (TMCI) Company Profile
Name
Treace Medical Concepts Inc
Sector
Industry
Phone
(904) 373-5940
Address
100 PALMETTO PARK PLACE, PONTE VEDRA
Compare TMCI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMCI
Treace Medical Concepts Inc
|
8.32 | 510.34M | 198.53M | -63.68M | -41.50M | -1.0222 |
|
ABT
Abbott Laboratories
|
131.93 | 228.81B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Treace Medical Concepts Inc Stock (TMCI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-31-24 | Initiated | Lake Street | Buy |
| Dec-17-24 | Resumed | JP Morgan | Neutral |
| May-16-24 | Downgrade | UBS | Buy → Neutral |
| May-08-24 | Downgrade | BTIG Research | Buy → Neutral |
| May-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-08-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-08-24 | Downgrade | Stifel | Buy → Hold |
| May-08-24 | Downgrade | Truist | Buy → Hold |
| Sep-29-23 | Initiated | UBS | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Apr-11-23 | Initiated | Stephens | Equal-Weight |
| May-12-22 | Initiated | BTIG Research | Buy |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-18-21 | Initiated | JP Morgan | Overweight |
| May-18-21 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-21 | Initiated | SVB Leerink | Outperform |
| May-18-21 | Initiated | Stifel | Buy |
View All
Treace Medical Concepts Inc Stock (TMCI) Latest News
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Sees Large Decrease in Short Interest - MarketBeat
Quantbot Technologies LP Buys Shares of 9,336 Treace Medical Concepts, Inc. (NASDAQ:TMCI) - Defense World
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives $10.14 Consensus Target Price from Analysts - MarketBeat
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives $10.14 Average PT from Analysts - Defense World
Charles Schwab Investment Management Inc. Sells 41,523 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) - MarketBeat
Treace Medical Concepts Studies of Procedures to Treat Mid-Foot Deformities Show Positive Results - Marketscreener.com
Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference - The Manila Times
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
45,923 Shares in Treace Medical Concepts, Inc. (NASDAQ:TMCI) Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Bank of New York Mellon Corp Has $937,000 Stock Holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) - Defense World
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference - TradingView
Revolutionary Bunion Treatment: Treace Launches 4 New Minimally Invasive Systems - Stock Titan
45,923 Shares in Treace Medical Concepts, Inc. (NASDAQ:TMCI) Purchased by Connor Clark & Lunn Investment Management Ltd. - Defense World
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Insider Sean F. Scanlan Sells 50,000 Shares - MarketBeat
Treace Medical Concepts (NASDAQ:TMCI) Trading 4.7% HigherShould You Buy? - MarketBeat
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Sees Large Increase in Short Interest - MarketBeat
William Blair Investment Management LLC Raises Position in Treace Medical Concepts, Inc. (NASDAQ:TMCI) - MarketBeat
Treace Medical Concepts chief innovation officer sells $398k in stock - Investing.com India
Treace Medical Concepts (NASDAQ:TMCI) Price Target Lowered to $9.50 at Truist Financial - MarketBeat
Truist Financial Lowers Treace Medical Concepts (NASDAQ:TMCI) Price Target to $9.50 - Defense World
Treace Medical Concepts (NASDAQ:TMCI) Shares Gap UpStill a Buy? - MarketBeat
John Treace Spends US$524k On Treace Medical Concepts Stock - Yahoo
Rhumbline Advisers Grows Holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) - Defense World
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Truist Financial Forecasts Strong Price Appreciation for Treace Medical Concepts (NASDAQ:TMCI) Stock - MarketBeat
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives $10.21 Consensus PT from Analysts - Defense World
Did Treace Medical Concepts, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateTMCI - ACCESS Newswire
Treace medical concepts CEO John Treace buys $524,064 in stock By Investing.com - Investing.com South Africa
Treace medical concepts CEO John Treace buys $524,064 in stock - Investing.com
Treace Medical Concepts (NASDAQ:TMCI) Given New $10.00 Price Target at Truist Financial - Defense World
Treace Medical Concepts (NASDAQ:TMCI) Announces Earnings Results - MarketBeat
Treace Medical’s Earnings Call Highlights Growth and Innovation - TipRanks
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q4 2024 Earnings Call Transcript - MSN
Deep Dive Into Treace Medical Concepts Stock: Analyst Perspectives (4 Ratings) - Benzinga
UBS Adjusts Treace Medical Concepts Price Target to $10 From $7.90, Maintains Neutral Rating - Marketscreener.com
Treace Medical Concepts Inc Stock (TMCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):